<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02588638</url>
  </required_header>
  <id_info>
    <org_study_id>NextGen-SE</org_study_id>
    <nct_id>NCT02588638</nct_id>
  </id_info>
  <brief_title>Next Generation Sequencing Diagnostics - On the Road to Rapid Diagnostics for Rare Diseases</brief_title>
  <acronym>NextGen-SE</acronym>
  <official_title>Next Generation Sequencing Diagnostics - On the Road to Rapid Diagnostics for Rare Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the study, NextGen SE are on-hand a cohort comprising each 50 pediatric and 50 adult
      patients, and in which there are an unclear movement disorder or an unclear cognitive
      disorder, examines the following questions :

      Primary:

        -  Number of diagnoses made by NGS

      Secondary:

        1. restriction of the quality of life by unclear disease

        2. Cost of not purposeful preliminary diagnostics ( beyond the minimal diagnostic data set
           )

        3. Impact of the diagnosis to therapy and follow-up examinations

        4. Time to diagnosis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the study NextGen SE (single-center, prospective, open diagnostic study) are on-hand a
      cohort comprising each 50 pediatric and 50 adult patients, and in which there are an unclear
      movement disorder or an unclear cognitive disorder, examines the following questions:

      Primary:

        -  Number of diagnoses made by next-generation sequencing (NGS)

      Secondary:

        1. Restriction of the quality of life by unclear disease

        2. Cost of not purposeful preliminary diagnostics (beyond the minimal diagnostic data of
           the diagnosis to therapy and follow-up examinations

        3. Time to diagnosis
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2015</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>Number of diagnoses made by next gereration sequency (NGS)</measure>
    <time_frame>Within the study period of 18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Restriction of the quality of life by unclear disease measured rated by Quality of Life Questionnaire (EQ5D), Depression Questionnaire (PHQ)</measure>
    <time_frame>At day 1</time_frame>
    <description>EQ-5D: Calculation preference value PHQ: Categorical analysis carried out by modified evaluation algorithms of the Diagnostic and Statistical Manual of Mental Disorders (DSM) -IV B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost of not purposeful preliminary diagnostics rated by questionnaire on costs (number of outpatient performances, stationary investigations, repetition 's imaging, genetic single diagnostics, high-priced diagnostic</measure>
    <time_frame>At day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to diagnosis</measure>
    <time_frame>At day 1</time_frame>
    <description>For patients whose diagnosis can be made by NGS</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Movement Disorder</condition>
  <condition>Cognitive Decline</condition>
  <arm_group>
    <arm_group_label>Adult patients</arm_group_label>
    <description>Unclear movement disorder, unclear cognitive decline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients &lt; 18 years</arm_group_label>
    <description>Patients with (penetrating) suspected cerebral neurogenetic diseases</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with unclear diagnoses
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        For patients&gt; 18 years

          1. Unclear movement disorder

             o Progressive ataxia after minimal exclusion diagnostics: magnetic resonance
             tomography (MRT) (structural lesions such as cerebellar tumor, malformation)
             Laboratory (Vitamin B12, thyroid peroxidase (TPO) antibodies, glutamate decarboxylase
             (GAD) II-antibodies (AK) In medullary lesions: Liquor exclusion Friedreich ataxia
             (FRDA) and spinocerebellar ataxia type (SCA)1-2-3-6

             o Progressive para-spasticity by minimal exclusion diagnostics: MRT neuro axis
             (structural lesions such as cervical myelopathy) Laboratory (Vitamin B12, human T-cell
             lymphotrophic virus ((HTLV)-AK) In medullary lesions: Liquor

          2. Unclear cognitive decline o After minimal exclusion diagnosis MRT (intracranial
             pressure, focal brain lesions explanatory) laboratory (Thyroid-stimulating hormone
             (TSH), TPO-AK, antibody profile limbic encephalitis) Liquor (inflammation, meningitis)
             Electroencephalography (EEG) (Status) Exclusion chromosome 9 open reading frame 72
             (C9orf72)

        For patients &lt;18 years Patients with (penetrating) suspected cerebral neurogenetic diseases

          -  Unclear movement disorder (spasticity, ataxia, dyskinesia)

          -  Unclear cognitive disorder with probability of monogenic origin

          -  Fragile X Syndrome (Fra-X) at mentally retarded boy, Friedreich ataxia (FRDA) with
             ataxia should be genetically excluded

        Exclusion Criteria:

        For patients &gt; 18 years

          1. Lack of consent

          2. symptom onset &gt; 40 years of age

          3. Sudden, abrupt beginning

          4. As early as previous history of genetic diagnosis using next-generation sequencing
             (NGS), also in the form of a panel

        For patients &lt;18 years

          1. injury brain disorders

               -  On the basis of imaging

               -  On the basis of medical history (premature baby, hypoxic-ischemic encephalopathy)

          2. Inflammatory brain disorders

               -  On the basis of imaging

               -  On the basis of laboratory parameters (Oligoclonal fractions, cerebrospinal fluid
                  (CSF) cell count increased)

          3. Light, isolated mental developmental disorder or behavioral disorder (rare
             monogenetic) - (less than 2 standard deviartion of normal or - &lt; 6 year olds - less
             than 1 year in development history back)

          4. Sudden , abrupt beginning

          5. Next-generation sequencing (NGS) also in the form of a panel
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ludger Schöls, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Tübingen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ludger Schöls, Prof. Dr.</last_name>
    <phone>+49 7071 29-80445</phone>
    <email>ludger.schoels@uni-tuebingen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Janine Magg, Dr.</last_name>
    <phone>+49 7071 29-80445</phone>
    <email>janine.magg@med.uni-tuebingen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Tubingen</city>
        <state>Baden-Württemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ludger Schöls, Prof. Dr.</last_name>
      <phone>+49 7071 29 80445</phone>
      <email>ludger.schoels@uni-tuebingen.de</email>
    </contact>
    <contact_backup>
      <last_name>Janine Magg, Dr.</last_name>
      <phone>+49 7071 29 80445</phone>
      <email>janine.magg@med.uni-tuebingen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Ludger Schöls, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 15, 2015</study_first_submitted>
  <study_first_submitted_qc>October 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2015</study_first_posted>
  <last_update_submitted>October 30, 2017</last_update_submitted>
  <last_update_submitted_qc>October 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Tuebingen</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Ludger Schöls</investigator_full_name>
    <investigator_title>Head of the Section Clinical Neurogenetics</investigator_title>
  </responsible_party>
  <keyword>NGS</keyword>
  <keyword>Quality of life</keyword>
  <keyword>Diagnosis</keyword>
  <keyword>Rare disease</keyword>
  <keyword>Next-generation sequencing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rare Diseases</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
    <mesh_term>Movement Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

